Institutional Sign In

Go

Amgen Czech Republic - Indebtedness

Net Debt/EBITDA & Net Debt/Equity
Pharmaceutical | Czechia | April 2, 2020
$2.99
Excel Sheet

Amgen Czech Republic's net debt stood at CZK -0.283 mil and accounted for -0.147% of equity at the end of 2017. The ratio is down 0.022 pp compared to the previous year.

Historically, the firm’s net debt to equity reached a high of 38.7% in 2015 and a low of -80.1% in 2005 between 2005 and 2017. The average for the last five years was 11.4%.

Net debt to EBITDA was calculated at -0.006x at the end of the year. That is down from 0x seen in 2012. The ratio reached a high of 1.53x in 2015 and a low of -2.63x in 2008.

The company’s cost of funding amounted to in 2017, down which is above the 5-year of 475%. Funding costs have “eaten” some 0.69% of the operating profit generated in 2019.

You can see all the company’s data at Amgen Czech Republic profile, or you can download a report on the company in the report section.